RIEMSER Arzneimittel AG Purchases Curasan Dental Product Line
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--RIEMSER Arzneimittel AG, a German pharmaceutical company, has purchased the worldwide specialty dental business of Curasan AG, including its three leading products: Cerasorb®, EpiGuide®, and REVOIS®. Curasan Inc., based in Research Triangle Park, NC, which had been marketing the family of bone regeneration and membrane products in the United States since 2004, will now be operating as RIEMSER Inc.
RIEMSER's official launch into the U.S. market will be at the American Academy of Periodontology's (AAP) 94th Annual Meeting (September 6–9, Seattle), the American Association of Oral and Maxillofacial Surgeons (AAOMS) conference (September 16-20, Seattle), and the American Academy of Implant Dentistry (AAID) Annual Meeting (October 29–November 2 in San Diego).
Norman Braun, Head of RIEMSER's Dental Division, noted that "Given the rapid growth in the US of Cerasorb® bone regeneration material and EpiGuide® membrane – which have doubled in users and sales during each of the past two years – we are eager to bring additional financial resources to the expansion of these and other dental products."
With annual revenues of €100 million ($149 million) and 650 employees at five manufacturing and research sites in Europe, RIEMSER develops and markets dental, dermatology, cardiovascular, anti-inflammatory, veterinary, and oncology products.
Rick Patton, Vice President of Sales of RIEMSER Inc., concurred: "We are excited about the recent RIEMSER acquisition because this will give us the ability to expand our products to our audience of oral surgeons, periodontists, and implantology specialists."
Workshops and lectures previously scheduled for the balance of 2008 by Drs. Bob Horowitz, Daniel Cullum, Ady Palti, Joel Rosenlicht, and Ziv Mazor will continue as planned. (The full list of workshops is available at http://www.curasan.de/usa/meetings_workshops/meetings_workshops.php.)
Copyright 2008 Business Wire All Rights Reserved.